Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a recent paper he co-authored with colleagues published in Wiley Online Library:
“Bispecific antibodies (BsAbs) in solid tumors are rapidly reshaping oncology.
Our pipeline analysis using Larvol CLIN shows:
- 681 trials, 183 BsAbs ( doubled since 2019)
- Heavy focus on GI, lung, breast and GYN cancers
- Dominant targets: PD1–CTLA4 (32%), PD1–VEGF, EGFR–MET
- Only 38% of trials biomarker-selected
- Innovation largely driven by biotech, not big pharma.”
Title: The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities
Authors: Rafik ElBeblawy, Chinmay Jani, Judith Pérez-Granado, Mark Gramling, Aakash Desai
Read the Full Article in Wiley Online Library.
More posts featuring Aakash Desai on OncoDaily.
